[go: up one dir, main page]

Sanghamitra et al., 2011 - Google Patents

Copper (I) complexes of modified nucleobases and vitamin B3 as potential chemotherapeutic agents: In vitro and in vivo studies

Sanghamitra et al., 2011

View PDF
Document ID
4290379323651724456
Author
Sanghamitra N
Adwankar M
Juvekar A
Khurajjam V
Wycliff C
Samuelson A
Publication year
Publication venue
Indian Journal of Chemistry-Part A InorganicPhysical Theoretical and Analytical

External Links

Snippet

Three new complexes of Cu (I) have been synthesized using ancillary ligands like thiopyrimidine (tp) a modified nucleobase, and nicotinamide (nic) or vitamin B3, and characterized by spectroscopy and X-ray crystallography. In vitro cytotoxicity studies of the …
Continue reading at www.academia.edu (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48007—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent
    • A61K47/48023—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent the modifying agent being an organic compound
    • A61K47/48061—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the pharmacologically- or therapeutically-active agent being covalently bound or complexed to a modifying agent the modifying agent being an organic compound the modifying agent being a heterocyclic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom

Similar Documents

Publication Publication Date Title
Icsel et al. New manganese (II), iron (II), cobalt (II), nickel (II) and copper (II) saccharinate complexes of 2, 6-bis (2-benzimidazolyl) pyridine as potential anticancer agents
Altaf et al. New bipyridine gold (III) dithiocarbamate-containing complexes exerted a potent anticancer activity against cisplatin-resistant cancer cells independent of p53 status
Galanski Recent developments in the field of anticancer platinum complexes
Xie et al. Anticancer and antiangiogenic iron (II) complexes that target thioredoxin reductase to trigger cancer cell apoptosis
Chen et al. Novel NHC-coordinated ruthenium (II) arene complexes achieve synergistic efficacy as safe and effective anticancer therapeutics
Ćoćić et al. New monofunctional platinum (II) and palladium (II) complexes: Studies of the nucleophilic substitution reactions, DNA/BSA interaction, and cytotoxic activity
Kurzwernhart et al. Structure–activity relationships of targeted RuII (η6-p-Cymene) anticancer complexes with flavonol-derived ligands
Yi et al. Synthesis, characterization and anticancer activity in vitro and in vivo evaluation of an iridium (III) polypyridyl complex
Hu et al. Copper (II) complexes based on quinoline-derived Schiff-base ligands: Synthesis, characterization, HSA/DNA binding ability, and anticancer activity
Chen et al. A ruthenium (II) β-carboline complex induced p53-mediated apoptosis in cancer cells
Xue et al. Platinum (II) compounds bearing bone-targeting group: synthesis, crystal structure and antitumor activity
Bjelogrlić et al. Synthesis, structure and characterization of novel Cd (II) and Zn (II) complexes with the condensation product of 2-formylpyridine and selenosemicarbazide: antiproliferative activity of the synthesized complexes and related selenosemicarbazone complexes
Filipović et al. Zn (II) complex with 2-quinolinecarboxaldehyde selenosemicarbazone: synthesis, structure, interaction studies with DNA/HSA, molecular docking and caspase-8 and-9 independent apoptose induction
Qin et al. Synthesis and in vitro biological evaluation of three 4′-(4-methoxyphenyl)-2, 2′: 6′, 2 ″-terpyridine iridium (III) complexes as new telomerase inhibitors
Liu et al. GLUT1-mediated selective tumor targeting with fluorine containing platinum (II) glycoconjugates
Tamasi et al. {Ru (CO) x}-Core complexes with benzimidazole ligands: synthesis, X-ray structure and evaluation of anticancer activity in vivo
Kalaiarasi et al. An investigation on 3-acetyl-7-methoxy-coumarin Schiff bases and their Ru (II) metallates with potent antiproliferative activity and enhanced LDH and NO release
Talancon et al. Diastereomerically pure platinum (II) complexes as antitumoral agents.: The influence of the mode of binding {(N),(N, O)− or (C, N)}− of (1S, 2R)[(η5-C5H5) Fe {(η5-C5H4) CHNCH (Me) CH (OH) C6H5}] and the arrangement of the auxiliary ligands
Sanghvi et al. Antitumor properties of five-coordinate gold (III) complexes bearing substituted polypyridyl ligands
Sanghamitra et al. Copper (I) complexes of modified nucleobases and vitamin B3 as potential chemotherapeutic agents: In vitro and in vivo studies
Wu et al. Development of a multi-target anticancer Sn (ii) pyridine-2-carboxaldehyde thiosemicarbazone complex
Harringer et al. Multifunctional Pt (iv) prodrug candidates featuring the carboplatin core and deferoxamine
CN105713047B (en) One eka-platinium (II) complex and its preparation method and application
Öztürkkan et al. Synthesis, crystal structure, potential drug properties for Coronavirus of Co (II) and Zn (II) 2-chlorobenzoate with 3-cyanopyridine complexes
CN116396229A (en) Preparation of a quinazoline compound and its antitumor application